Thinly traded micro cap Assembly Biosciences (ASMB +45.4%) is up on a 13x surge in volume. Shares have almost doubled in two days in response to positive data on HBV candidates ABI-H0731 and ABI-H2158. The results will be presented at The Liver Meeting in Boston next month.
Final results from a Phase 2a study of lead
candidate ABI-H0731 + nucleoside/tide analogs (Nrtl) in Hbe
antigen-positive HBV patients showed faster and greater declines in HBV
DNA and RNA compared to Nrtl alone.
Preliminary results from a Phase 1b trial
evaluating candidate #2 ABI-H2158 alone in Hbe antigen-positive HBV
patients showed declines in HBV DNA and RNA after 14 days of treatment
with a favorable safety profile.
https://seekingalpha.com/news/3506606-assembly-bio-45-percent-encouraging-data-hbv-candidates
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.